A total of five (6.8%) adverse events were reported among the nirmatrelvir/ritonavir recipients, including one mild liver dysfunction with elevated alanine transaminase and aspartate transaminase, one acute kidney injury, two patients experiencing vomiting, and one patient having transient dysgeusia. This evidence concerns the gene GPT and acute kidney injury.